Navigation Links
No Cancer Risk From Long-Acting Insulin: Studies
Date:6/12/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, June 11 (HealthDay News) -- Three studies should squelch fears that taking a form of insulin called insulin glargine (Lantus) increases the risk of cancer, researchers say.

Prior research had suggested an increase in cancer risk with Lantus, an injectable drug used to treat diabetes. "But, the worry we had that Lantus might be associated with cancer seems not to be the case, and people should continue using insulin," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City, who wasn't involved in these studies.

Lantus is a long-acting insulin, meaning patients need only one shot a day, rather than multiple injections, and it's easy to use, Mezitis added.

People using glargine often have type 1 diabetes, a condition in which the body can't make insulin, which is needed to regulate the amount of sugar in the blood. People with type 2 diabetes, the form linked to being overweight and sedentary, may also take insulin if lifestyle and dietary changes don't control their blood-sugar levels.

In the United States, where obesity and type 2 diabetes are soaring, Mezitis said he expects to see many more insulin users in years to come.

In each study, researchers wanted to see if there was any connection between daily doses of insulin and cancer.

The results were scheduled for presentation Monday at a meeting of the American Diabetes Association in Philadelphia.

In one study, Laurel Habel, a research scientist at the Kaiser Permanente Northern California Division of Research, and colleagues looked at the risk of cancer among 115,000 patients taking either glargine or an intermediate-acting insulin called NPH. This is usually taken twice a day.

"We looked at prostate, breast and colon cancer and all cancers combined," Habel said. "We saw no evidence that there was any relationship between glargine and the risk of these cancers."

In addition, no risk of cancer was noted among patients who switched from another long-acting insulin to glargine or in people who started on glargine first, Habel said.

But, these findings are based on short-term use of the drugs -- median duration was less than 1.5 years -- and she said additional follow-up is needed to evaluate cancer risk over the long-term. Cancer can take years to decades to develop, Habel noted.

In another trial, researchers from the University of North Carolina (UNC) looked at the risk of cancer in more than 52,000 people taking glargine or NPH.

Over two years of follow-up, the researchers found no association between either form of insulin and the risk for any cancer.

The UNC team used data from the Northern European Study of Insulin and Cancer, which included more than 447,000 patients, and found no spike in cancer risk for glargine or any other insulin.

"There was absolutely no association at all between the risk of cancer and any form of insulin," researcher Peter Boyle, president of the International Prevention Research Institute in Lyon, France, said during a Monday press conference. The researchers had looked for risk of all cancers, plus risks for cancers of the breast, lung, pancreas, lung, colon and prostate.

"There was absolutely no causal association," he added.

In yet another study, Dr. Hertzel Gerstein, a professor of medicine at McMaster University in Hamilton, Ontario, Canada, and colleagues found no raised risk of cancer or heart disease in a study of insulin involving more than 12,500 participants.

"At the end of the day, the study showed that one injection of insulin a day had a neutral effect on heart attacks, strokes and deaths. In addition, it had no effect on other outcomes like cancers," Gerstein said.

No protective effects on cardiovascular health or cancer were seen from insulin either, according to the report, published in the June 11 online edition of the New England Journal of Medicine.

Data and conclusions presented at medical meetings should be considered preliminary until published in a peer-reviewed medical journal.

More information

For more information on diabetes, visit the American Diabetes Association.

SOURCES: Laurel Habel, Ph.D., research scientist, Kaiser Permanente Northern California Division of Research, Oakland, Calif.; Hertzel Gerstein, M.D., professor, medicine, McMaster University department of medicine, Hamilton, Canada; Spyros Mezitis, M.D., endocrinologist, Lenox Hill Hospital, New York City; June 11, 2012, news conference, Peter Boyle, Ph.D., president, International Prevention Research Institute, Lyon, France; June 11, 2012, presentations, American Diabetes Association meeting, Philadelphia; June 11, 2012, New England Journal of Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
No Cancer Risk From Long-Acting Insulin: Studies
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... service members that have been wounded in battle and their families. Venture Construction Group ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology: